Commission Regulation (EC) No 1875/2004 of 28 October 2004 amending Annexes II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin as regards sodium salicylate and fenvalerateText with EEA relevance
Date: 2004-10-28
Institutions: European Commission
Subjects: European standard, animal product, human nutrition, pharmaceutical legislation, veterinary drug

29.10.2004

EN

Official Journal of the European Union

L 326/19

COMMISSION REGULATION (EC) No 1875/2004

of 28 October 2004

amending Annexes II and III to Council Regulation (EEC) No 2377/90 laying down a Community
procedure for the establishment of maximum residue limits of veterinary medicinal products in
foodstuffs of animal origin as regards sodium salicylate and fenvalerate

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

concerning that substance, and the validity of the provi-
sional maximum residue limits
should therefore be
extended to 1 July 2006.

Having regard to the Treaty
Community,

establishing the European

(4)

Regulation (EEC) No 2377/90 should be amended
accordingly.

Having regard to Council Regulation (EEC) No 2377/90 of 26
June 1990 laying down a Community procedure for the estab-
lishment
veterinary
medicinal products in foodstuffs of animal origin (1), and in
particular Article 3 and the third paragraph of Article 4 thereof,

of maximum residue

limits

of

Having regard to the opinions of the European Agency for the
Evaluation of Medicinal Products formulated by the Committee
for Veterinary Medicinal Products,

Whereas:

(1)

(2)

(3)

All pharmacologically active substances which are used
within the Community in veterinary medicinal products
intended for administration to food-producing animals
should be evaluated in accordance with Regulation
(EEC) No 2377/90.

The substance sodium salicylate has been included in
Annex II for all food producing species except fish but
only for topical use. The entry should be extended to
cover oral use in bovine and porcine species, with the
exception of
animals producing milk for human
consumption.

The provisional maximum residue limit for fenvalerate
to
expires on 1 July 2004.
studies
the
allow for

It has proven expedient

completion of

scientific

the

(1) OJ L 224, 18.8.1990, p. 1. Regulation as

(EC) No 1851/2004 (OJ

last amended by
L 323,

Commission Regulation
26.10.2004, p. 6).

(5)

(6)

any

to make

An adequate period should be allowed before the applic-
ability of this Regulation in order to enable Member
States
adjustment, which may be
necessary in the light of this Regulation, to the author-
isations
to place the veterinary medicinal products
concerned on the market, which have been granted in
accordance with Directive 2001/82/EC of the European
Parliament and of the Council of 6 November 2001 on
the Community code relating to veterinary medicinal
products (2), to take account of the provisions of this
Regulation.

The measures provided for in this Regulation are in
Standing
the
the
accordance with
Committee on Veterinary Medicinal Products,

opinion

of

HAS ADOPTED THE FOLLOWING REGULATION:

Article 1

Annexes
amended in accordance with the Annex to this Regulation.

to Regulation (EEC) No 2377/90 are

II and III

Article 2

This Regulation shall enter into force on the third day following
its publication in the Official Journal of the European Union.

It shall apply from 28 December 2004.

(2) OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive

2004/28/EC (OJ L 136, 30.4.2004, p. 58).

L 326/20

EN

Official Journal of the European Union

29.10.2004

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 28 October 2004.

For the Commission

Olli REHN
Member of the Commission

29.10.2004

EN

Official Journal of the European Union

L 326/21

s
e
u
s
s
i
t

t
e
g
r
a
T

e
l
c
s
u
M

r
e
v
i
L

t
a
F

y
e
n
d
K

i

k

l
i

M

s
L
R
M

g
k
/
g

μ

5
2

g
k
/
g

μ

g
k
/
g

μ

g
k
/
g

μ

g
k
/
g

μ

0
5
2

5
2

5
2

0
4

s
e
i
c
e
p
s

l
a
m
n
A

i

e
u
d
i
s
e
r

r
e
k
r
a

M

)
s
(
e
c
n
a
t
s
b
u
s

e
v
i
t
c
a

y
l
l
a
c
i
g
o
l
o
c
a
m
r
a
h
P

e
n
i
v
o
B

d
n
a

S
R

,

S
S

,

R
R

f
o

m
u
s
(

e
t
a
r
e
l
a
v
n
e
F

)
s
r
e
m
o
s
i

R
S

)
1
(
e
t
a
r
e
l
a
v
n
e
F

‘

s
d
i
o
r
h
t
e
r
y
P

.

’

.

6
0
0
2

y
l
u
J

1

n
o

e
r
i
p
x
e

s
L
R
M

l
a
n
o
i
s
i
v
o
r
P

)
1
(

.

3
2
2

.

)
1
(
e
n
i
c
r
o
p

,
e
n
i
v
o
B

s
e
i
c
e
p
s

l
a
m
n
A

i

)
s
(
e
c
n
a
t
s
b
u
s

e
v
i
t
c
a

y
l
l
a
c
i
g
o
l
o
c
a
m
r
a
h
P

s
d
n
u
o
p
m
o
c

c
i
n
a
g
r
O

.

2

e
t
a
l
y
c
i
l
a
s

m
u
i
d
o
S

‘

’

.

n
o
i
t
p
m
u
s
n
o
c

n
a
m
u
h

r
o
f

d
e
c
u
d
o
r
p

s
i

k

l
i

m

h
c
i
h
w

m
o
r
f

s
l
a
m
n
a

i

n

i

e
s
u

r
o
f

t
o
n

;
e
s
u

l
a
r
o

r
o
F

)
1
(

X
E
N
N
A

.

0
9
/
7
7
3
2

o
N

)

C
E
E
(

n
o
i
t
a
l
u
g
e
R

o
t

I
I

x
e
n
n
A

n

i

d
e
t
r
e
s
n

i

)
e
r
a
(

s
i

)
s
(
e
c
n
a
t
s
b
u
s

i

g
n
w
o

l
l

o
f

e
h
T

.

A

.

0
9
/
7
7
3
2

o
N

)

C
E
E
(

n
o
i
t
a
l
u
g
e
R

o
t

I
I
I

x
e
n
n
A

n

i

d
e
t
r
e
s
n

i

)
e
r
a
(

s
i

)
s
(
e
c
n
a
t
s
b
u
s

i

g
n
w
o

l
l

o
f

e
h
T

.

B

s
e
t
i
s
a
r
a
p
o
t
c
e

t
s
n
i
a
g
a

g
n
i
t
c
a

s
t
n
e
g
A

s
t
n
e
g
a

c
i
t
i
s
a
r
a
p
i
t
n
A

.

2
2

.

.

2